Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Eli Lilly’s Obesity Franchise Is Expanding Fast—What’s The Real Upside Beyond Zepbound?

Eli Lilly $4 Billion Takeover Trail: How Three Small Vaccine Targets Could Add Big Optionality!

Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head!

Douglas Research Advisory

Equity Capital Markets

OliX Pharmaceuticals / Equity Capital Markets

<ul>
<li>OliX Pharmaceuticals announced that it plans to conduct a capital raise through a third-party allocation worth approximately 111 billion won to raise operating funds, including for research and development.</li>
<li>The investors participating in this capital raise include L'Oréal Group's venture fund, Weiss Asset Management, and Brookdale International Partners.</li>
<li>Overall, I have a Positive View of this capital raise. OliX is raising a capital of 111 billion won from top-tier investor base including L'Oréal Group's venture fund.</li>
</ul>


OliX Pharmaceuticals announced that it plans to conduct a capital raise through a third-party allocation worth approximately 111 billion won to raise operating funds, including for research and development.
The investors participating in this capital raise include L'Oréal Group's venture fund, Weiss Asset Management, and Brookdale International Partners.
Overall, I have a Positive View of this capital raise. OliX is raising a capital of 111 billion won from top-tier investor base including L'Oréal Group's venture fund.


OliX Pharm: Capital Raise of 111 Billion Won from Investors Including L'Oreal's Venture Fund